U.S. Consumer Durables Stock News

Roche’s persevERA Phase 3 breast cancer trial with giredestrant previously failed to meet its primary endpoint of improving progression-free survival, sparking renewed scrutiny of estrogen receptor–targeting therapies across the sector. Olema Pharmaceuticals’ separate palazestrant program, developed with Pfizer and Novartis and still in Phase 3 trials, has drawn attention as investors weigh whether its differentiated profile can set it apart from Roche’s setback. We’ll now look at how the...

Yext (YEXT) has wrapped up FY 2026 with fourth quarter revenue of US$112.0 million and basic EPS of US$0.03, alongside trailing twelve month revenue of US$446.6 million and EPS of US$0.31 that reflect its move into profitability over the past year. The company has seen quarterly revenue hold in a tight band between US$109.5 million and US$113.1 million since early FY 2026, while basic EPS has ranged from US$0.01 in Q1 to US$0.22 in Q2, a clear shift from losses in FY 2025 where quarterly EPS...

Taylor Morrison Home (NYSE:TMHC) is reporting a sharp decline in its order backlog after struggling to secure new home orders over the past two years. The company now faces expectations of lower revenue over the next 12 months, pointing to weaker demand conditions for its homebuilding operations. This shift in backlog and demand outlook marks a material change in operational momentum that has not been widely discussed yet. Taylor Morrison Home, a major US homebuilder focused on single...

If you are wondering whether Select Medical Holdings is fairly priced or offering value at today’s levels, you are not alone. This article is built to help you judge the stock through a clear valuation lens. The share price closed at US$16.26 most recently, with returns of 0.0% over 7 days, 3.6% over 30 days, 9.7% year to date, a 2.5% decline over 1 year, a 26.2% gain over 3 years, and a 6.4% decline over 5 years. This gives a mixed picture for investors weighing risk and potential...

Wondering if Hamilton Lane is attractively priced at around US$104.48, or if the market is asking too much for the shares right now? This article walks through that question step by step so you can judge the valuation for yourself. The stock has seen a 2.7% decline over the last 7 days, a 20.7% decline over the last 30 days, and a 23.5% decline year to date, while the 1 year return sits at a 24.3% decline and the 3 year and 5 year returns are 66.4% and 29.0% respectively. Those mixed results...

In February 2026, Structure Therapeutics Inc. reported fourth-quarter 2025 results showing net income of US$33 million, compared with a net loss of US$36.48 million a year earlier. On the same day, the company also filed a US$235.64 million shelf registration for 3,541,890 American Depositary Shares tied to an employee stock plan, signaling preparations for potential future capital needs. We’ll now explore how this shift to quarterly profitability, alongside the new shelf registration,...

Event context and recent price moves Fidelity National Financial (FNF) has recently seen a 2.1% one day decline, adding to a 4.5% pullback over the past week and a steeper slide over the past month and past 3 months. In this context, the stock now sits at $48.40, with trailing 1 year total return at a 16.2% decline and year to date performance also in negative territory. This may prompt investors to revisit how current pricing lines up with fundamentals. See our latest analysis for Fidelity...

Why Victoria's Secret stock is in focus after earnings and guidance Victoria's Secret (VSCO) is back in the spotlight after releasing quarterly results that exceeded earnings forecasts and paired strong sales with confident guidance for the coming quarter and full year 2026. The update has given investors fresh numbers to weigh, as the company outlines expectations for demand while also facing questions around profitability trends and ongoing decisions about its non core digital and styling...

Uranium Energy (UEC) has posted Q2 2026 revenue of US$20.2 million, with a basic EPS loss of US$0.03 and net income loss of US$13.9 million, providing a clear snapshot of where the business stands today. Over recent quarters, the company has reported revenue between US$0 and US$49.75 million while basic EPS has ranged from a loss of US$0.02 to a loss of US$0.07. This gives investors a wide view of how the top line and per-share results have shifted through different periods. With forecasts...

If you are wondering whether Western Digital's current share price still offers value after a big run, this article will walk through what the numbers are really saying about the stock. Western Digital recently closed at US$266.22, with a 6.2% return over the last 7 days, a 5.8% decline over 30 days, a 41.8% return year to date, and a very large 1-year gain of more than 5x. Recent headlines around Western Digital have focused on its position in data storage and memory solutions and how...

LifeMD (LFMD) has wrapped up FY 2025 with Q4 revenue of about US$46.9 million and basic EPS of around a US$0.04 loss, alongside trailing twelve month revenue of roughly US$194.1 million and basic EPS of about a US$0.32 loss. Over the past few reported periods, revenue has moved from US$64.3 million in Q4 2024 to US$65.7 million in Q1 2025, then US$61.1 million in Q2, US$60.2 million in Q3 and US$46.9 million in Q4. Quarterly EPS shifted from roughly a US$0.02 loss in Q4 2024 to a small profit...

Mosaic (MOS) is back in the spotlight as law firms review potential fiduciary duty issues tied to a federal probe into alleged fertilizer price fixing, raising fresh questions about legal risk and longer term shareholder exposure. See our latest analysis for Mosaic. At a share price of US$26.48, Mosaic has seen a 7.41% 1 month share price decline after legal headlines and mixed sentiment following its recent earnings report, even though the 90 day share price return of 11.49% and 1 year total...

Domino's Pizza (DPZ) is back in focus after reporting strong fourth quarter results, with global retail sales growth, positive U.S. same store sales, and a 15% dividend increase catching investor attention. See our latest analysis for Domino's Pizza. Even with the latest quarterly update and dividend increase, Domino's recent share price performance has been mixed. The 1 month share price return is 1.43%, and the 1 year total shareholder return reflects a 5.49% decline. However, the 3 year...

Prelude Therapeutics (PRLD) has just posted its FY 2025 numbers, with Q4 revenue of US$5.6 million, a basic EPS loss of US$0.21, and net income excluding extra items showing a loss of US$16.5 million. Over recent quarters the company has seen revenue move from US$4 million in Q4 2024 to US$6.5 million in Q3 2025 before landing at US$5.6 million in Q4 2025, while basic EPS has ranged from a loss of US$0.38 in Q4 2024 to a peak quarterly loss of US$0.42 in early 2025 and then US$0.21 in the...

AT&T (NYSE:T) has announced a US$250b U.S. network investment initiative tied to the 150th anniversary of the telephone. The plan targets fiber, 5G, wireless, and satellite expansion, along with workforce development and AI-focused upskilling. The company also plans new public safety and network security efforts, as well as public private collaborations across all regions. For you as an investor, this marks one of the largest infrastructure commitments ever announced by AT&T, a core player...

Wondering whether Merck's current share price really reflects its value, or if there is still room on the table for long term investors? Merck's stock closed at US$117.09 recently, with a 2.3% decline over the last 7 days and a 4.0% decline over 30 days, although the shares show returns of 10.0% year to date and 28.3% over the last year. Recent headlines around Merck have kept attention on its pipeline and broader pharmaceutical footprint. This helps frame how investors think about future...

Aurinia Pharmaceuticals (AUPH) just paired a strong 2025 earnings release with fresh 2026 guidance, outlining expectations for total revenue of US$315 million to US$325 million and net product sales of US$305 million to US$315 million. See our latest analysis for Aurinia Pharmaceuticals. At a share price of US$14.80, Aurinia’s recent 1 day share price return of 2.99% and 7 day share price return of 4.59% follow the 1 year total shareholder return of 78.53%. This comes even though the 90 day...

In early 2026, FedEx faced scrutiny after US customers reported unexpectedly high tariff-related fees on relatively low-value imports, while the company also reported stronger-than-expected earnings and raised its fiscal-year outlook supported by cost-cutting initiatives. This combination of legal disputes over tariff billing practices and improving profitability from efficiency measures highlights the operational and regulatory crosscurrents shaping FedEx’s business today. With FedEx’s...

If you are wondering whether Rocket Lab's current share price still makes sense after such a strong run, you are not alone. This article is going to focus squarely on what you are paying versus what you are getting. The stock closed at US$68.93, with returns of a 1.7% decline over 7 days, a 4.7% decline over 30 days, a 9.3% decline year to date and 286.6% over 1 year. The 3 year return is very large and the 5 year return is also very large, which naturally raises questions about how much...

BlackRock CEO Larry Fink is warning that new tariffs could add to inflation pressures and raise everyday costs for Americans. Fink is urging households to reassess retirement savings plans and not rely only on Social Security benefits. He is encouraging Americans to seek professional financial advice to prepare for potentially higher long term living costs. For investors watching NYSE:BLK, these comments come as the stock trades at $967.36, with a 3 year return of 62.8% and a 5 year return...

In early March 2026, Teva Pharmaceutical Industries’ CEO Richard D. Francis used a series of major healthcare conferences in the US and UK to outline the company’s “Pivot to Growth” strategy, emphasizing innovation, biosimilars expansion, and a new financing partnership with Blackstone to accelerate product development. The company’s plan to introduce an innovative product roughly every 18 months through the 2030s, including expanded indications for AUSTEDO, UZEDY, olanzapine, and AJOVY,...

In early March 2026, Core Scientific, Inc. and the Cadillac Formula 1 Team announced a multi-year global partnership naming Core Scientific as Official Data Center Partner, with the company guiding the team’s secure, scalable, high-density data hub at its new Indianapolis headquarters and supporting race-critical simulation, engineering and manufacturing workloads across U.S. and U.K. operations. Beyond branding on the Cadillac Formula 1 cars, this collaboration highlights Core Scientific’s...

Chevron (CVX) is back in focus as crude prices sit near historic highs, lifted by the Iran conflict, disruptions in the Strait of Hormuz, and OPEC+ cuts, while its Venezuela expansion adds another source of attention. See our latest analysis for Chevron. Those geopolitics driven oil swings are showing up in Chevron’s chart, with a 23.0% 90 day share price return and 19.5% year to date gain. The 5 year total shareholder return of 113.1% points to substantial long run value creation. If you are...

If you are wondering whether M&T Bank at around US$204 a share is still offering value after a strong run, you are not alone. This article is designed to help you assess what that price really represents. The stock has pulled back recently, with an approximate 6.8% decline over the last 7 days and 14.2% over the last 30 days, while still showing a 22.8% return over 1 year and 77.1% over 3 years. Recent coverage around US regional banks has kept attention on balance sheet strength, credit...